Atmo Biosciences partners with ps.healthcare to expand Machine Learning (ML) and Artificial Intelligence (AI) capabilities
October 26, 2023.
Atmo Biosciences today announced it is partnering with ps.healthcare to shape its data strategy, and create a roadmap of future applications using machine learning (ML) and artificial intelligence (AI).
Atmo Biosciences is building the world’s only dataset of gastrointestinal gas profiles. This data provides insight into gut health and microbiome function and is collected from both healthy patients and those with wide ranging gastrointestinal disorders using Atmo’s unique gas-sensing capsule system. The partnership with ps.healthcare will accelerate Atmo’s ability to extract data from this growing dataset.
ps.healthcare specializes in investing in, developing, and collaborating with AI-powered, digital, and tech-enabled healthcare companies. It is founded by Dr. Peter Cronin, an experienced healthcare leader and co-founder of successful health data analytics firm Prospection. ps.healthcare brings together experts with a proven track record of applying AI-powered innovation to produce commercially valuable outcomes.
Atmo Biosciences Head of R&D and Product Development, Dr. James John, said: “This is a timely engagement given we have a mature product platform that is fast approaching market entry. The Atmo Gas Capsule will generate thousands of individual GI gas profiles, and we are setting Atmo up to be able to leverage this dataset with fast-evolving AI and ML tools to expand our product capabilities and applications.”
Atmo Biosciences CEO Mal Hebblewhite added: “With a unique blend of experience in health, real world data platforms, digital products, and AI solutions, ps.healthcare is a great partner for Atmo Biosciences to extract value from our dataset, helping to improve patient outcomes and contributing to Atmo’s long-term growth.”
ps.healthcare founder Peter Cronin said: “Atmo Biosciences’ technology is truly groundbreaking and offers unparalleled insights into gut health and microbiome function. We’re very excited to be working with the Atmo team at the intersection of data, technology, and healthcare. We believe our combined expertise can spark progress, innovate solutions, and contribute to a healthier future.”